Colombia and Abbott in price talks on HIV drug
This article was originally published in Scrip
Executive Summary
The Colombian government is having talks with Abbott Laboratories because it wants the company to cut the price of its HIV therapy, Kaletra/Aluvia (lopinavir plus ritonavir), to $900 per patient per year, or to at least match the prices of neighbouring countries.